This webinar examines the hot topics in immunoassay bioanalysis for biotechs navigating the immunogenicity and biomarker requirements for clinical trials. Join the discussion with panelists from Agliex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, and B2S Life Sciences, a biotherapeutic enablement company advancing improved analytical methods and outcomes for developers of biotherapeutic drugs and diagnostics
Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today announced the purchase of leading biolab TetraQ, based out of the University of Queensland.
Agilex Biolabs CEO Jason Valentine said the Board and senior management at Agilex Biolabs were extremely pleased with the purchase of such a high-calibre bioanalytics company.
“TetraQ complements the Agilex Biolabs work in Australia and APAC with its expert staff and years of experience in regulated bioanalytical services,” he said.
Agilex Biolabs CEO Jason Valentine said the Board and senior management at Agilex Biolabs were extremely pleased with the purchase of such a high-calibre bioanalytics company.
“TetraQ complements the Agilex Biolabs work in Australia and APAC with its expert staff and years of experience in regulated bioanalytical services,” he said.
Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today announced it will showcase its world-class immunoassay and immunobiology services for regulated bioanalysis at Bio-Europe 2021.
Demand for APAC clinical trials is still on the rise as COVID numbers continue to fall across the region attracting biotechs wanting to restart stalled or paused clinical trials from around the globe. Indeed Australia recorded zero new cases in the past 25 days.
Agilex Biolabs, Australia’s most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, today announced the roll-out of the GALEXI™ client portal for real-time study management.
Agilex Biolabs, Australia’s most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, today announced the roll-out of the GALEXI™ client portal for real-time study management.
Agilex Biolabs is the leading bioanalytical laboratory in Asia-Pacific with the most advanced platforms for sensitive technologies. They include Sciex API 6500+ LC-MS/MS, Sciex API 4000 LC-MS/MS systems; Gyrolab™ Xplore, Luminex MAGPIX xPONENT ™, MSD Quickplex 120 and BD FACSymphony™ A3 20 colour flow cytometry analysers, so we have the capability to deliver any sized project.
Register here (free)...
Agilex Biolabs, the leading APAC biolabs for biotech clinical trials, announced today the launch of a Client Portal named GALEXI™.
The Agilex Biolabs technology team, with its Microsoft partner, accelerated the launch of GALEXI™ to deliver secure and enhanced communications during continued COVID challenges globally.
The Agilex Biolabs technology team, with its Microsoft partner, accelerated the launch of GALEXI™ to deliver secure and enhanced communications during continued COVID challenges globally.
Agilex Biolabs, Australia’s most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, congratulates client company Shasqi on the announcement of the first-ever application of click chemistry in humans, with the launch of the Company’s lead clinical candidate, SQ3370. Shasqi is the first Y Combinator-backed biotech company to reach clinical development.
Title: Development and Validation of a PK Method for Tocilizumab in Both Singlicate and Duplicate on the Gyrolab Platform
Agilex Biolabs, Australia’s most advanced specialist bioanalytical laboratory for clinical trials, congratulated client Zelira Therapeutics on their Phase 2 Medicinal Cannabis Insomnia Study.
Why Australia is the World’s Leading Early Phase Destination – Rapid Start-up, No IND Required, and a Government-Backed Refund on Almost Half of all Trial Costs Increasingly Sponsors are wanting to be actively involved in the core clinical partner selection because they matter to the success of their clinical research.
Hi, everyone. I'm Arsalan Arif, the publisher of Endpoints News, and I'm pleased to be your moderator today. Today's webinar is sponsored by Agilex Biolabs in Australia. Our topic is Why Australia is the World's Leading Early Phase Destination - Rapid Start-up, No IND Required, and a Government-Backed Refund on Almost Half of all Trial Costs. I'm joined by two great guests today. Kurt Sales, the Director of Immunoassay at Agilex Biolabs, and Jane Kelly, the CEO of CMAX Clinical Research.
Award-winning Agilex Biolabs, the Asia-Pacific region’s leading bioanalytical laboratory for clinical trials, based in Australia, has developed the world’s most accurate cannabinoid assay.
Gathering together the key clinical service providers for a trial can be a daunting process – especially if you are going off-shore to reactivate trials or start new trials to make up for COVID delays.
However, Australia offers a refreshingly streamlined process because of its group of proven top-tier providers that regularly work together so are fully engaged and in sync with processes and each other’s requirements and capabilities. This makes setting up trials in Australia a smooth, professional, and rapid process for biotechs. This webinar looks at how moving trials to Australia could be much easier than you think.
However, Australia offers a refreshingly streamlined process because of its group of proven top-tier providers that regularly work together so are fully engaged and in sync with processes and each other’s requirements and capabilities. This makes setting up trials in Australia a smooth, professional, and rapid process for biotechs. This webinar looks at how moving trials to Australia could be much easier than you think.
All right. Hi everybody. I’m Arsalan Arif, the publisher of Endpoints News and I’m pleased to be your moderator today. Today’s webinar is sponsored by Agilex Biolabs in Australia and our topic is the Australian Advantage, de-risk your early phase trials. I’m joined by Dr Kurt Sales today with Agilex Biolabs. He’s got an approximately 20 minute presentation and we’re going to follow it up with a quick Q&A. And now I give you Dr Kurt Sales.
Agilex Biolabs, Australia’s largest specialist bioanalytical laboratory for clinical trials, and Endpoints News launched a new webinar “How Easy is it to Move Your Trials to Australia” at BIO Asia-Taiwan 2020.
Agilex Biolabs, Australia’s largest specialist bioanalytical laboratory for clinical trials, encouraged biotechs to consider Australia for their clinical trials during a presentation at BIO Digital 2020.
Agilex Biolabs, Australia’s largest specialist bioanalytical laboratory for biotech clinical trials, is presenting the Australian Advantage including the world’s most attractive rebate on clinical trials costs, at BIO Korea 2020.
The reality is, Australia has fantastic key opinion leaders, some great principal investigators that have been running clinical trials for decades. The CROs, RFA with FDA and EMA requirements. And in fact, our whole Australian service provision industry sets itself to that standard because ultimately that is the client base that Australia is servicing. Most CROs in Australia and service providers will be able to talk about situations where their data has been presented to the FDA or EMA with success.
Video https://www.youtube.com/watch?v=sCUT8qtlRX4&feature=youtu.be...
Award-winning Australian bioanalytical laboratory Agilex Biolabs announced today it has appointed US-based Dr Caroline Popper, MBBS, MPH as Board Chair as part of its APAC clinical trials bioanalytics growth plans.
Award-winning Australian bioanalytical laboratory Agilex Biolabs announced today it has appointed PhD and NHMRC Fellow Patrick Hughes as R&D Manager Immunobiology.